Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells
about
Mechanisms of amino acid-stimulated insulin secretion in congenital hyperinsulinismSystemic Administration of Glibenclamide Fails to Achieve Therapeutic Levels in the Brain and Cerebrospinal Fluid of RodentsDifferential effects of drug interventions and dietary lifestyle in developing type 2 diabetes and complications: a systems biology analysis in LDLr-/- micePrioritizing Environmental Chemicals for Obesity and Diabetes Outcomes Research: A Screening Approach Using ToxCast™ High-Throughput DataWhy treatment fails in type 2 diabetesLessons from models of pancreatic beta cells for engineering glucose-sensing cellsStudy of the Effect of Panax Ginseng versus Gliclazide on Hyperglycaemia Induced by Dexamethasone in Experimental AnimalsAcute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes.Hyperinsulinism and diabetes: genetic dissection of beta cell metabolism-excitation coupling in miceDecreases in Gap Junction Coupling Recovers Ca2+ and Insulin Secretion in Neonatal Diabetes Mellitus, Dependent on Beta Cell Heterogeneity and NoiseABCC8 R1420H Loss-of-Function Variant in a Southwest American Indian Community: Association With Increased Birth Weight and Doubled Risk of Type 2 Diabetes.Pulsatile insulin secretion, impaired glucose tolerance and type 2 diabetes.A Mathematical Model of the Pathogenesis, Prevention, and Reversal of Type 2 DiabetesDecreasing cx36 gap junction coupling compensates for overactive KATP channels to restore insulin secretion and prevent hyperglycemia in a mouse model of neonatal diabetes.Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings.The diabetic β-cell: hyperstimulated vs. hyperexcited.Sulfonylureas: a new look at old therapy.A girl with permanent neonatal diabetes due to KCNJ11 mutation presented with Mauriac syndrome after improper adjustment in sulfonylurea dosage over 6 years.Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of K(ATP)-induced neonatal diabetes mellitus.Facilitation of ß-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac.Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy.HMR 1098 is not an SUR isotype specific inhibitor of heterologous or sarcolemmal K ATP channels.Suppression of KATP channel activity protects murine pancreatic beta cells against oxidative stress.Metformin compared with glyburide for the management of gestational diabetes.Antidiabetic drug glyburide modulates depressive-like behavior comorbid with insulin resistance.Nutrient sensing in pancreatic islets: lessons from congenital hyperinsulinism and monogenic diabetes.Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.Potentiation of Glibenclamide Hypoglycaemia in Mice by MK-467, a Peripherally Acting Alpha2-Adrenoceptor Antagonist.
P2860
Q27015645-35725B6E-AB00-491F-AB28-1A1AE60AC52CQ27301271-0DF1F7B0-55E2-44D9-81D6-485A536310C1Q28486194-0096C923-8FD2-49AD-9538-ACADFC173B80Q28831114-9E31D260-A5FE-42C2-81DC-A5F96A32F548Q33380396-CA068C9D-C03D-49AB-84E0-73247F021341Q34054232-FBD11EB0-BDAB-43B2-A7AB-6BB35A80E2F6Q34782632-CF973AA0-AFFB-435E-9C62-5002960DE029Q35227213-4935D510-B005-4143-912E-5C7F43B872ACQ35632861-85AE5270-0C20-4DA1-BFB8-365E7B33D74CQ36146862-18EAC1E5-EF8B-4E02-9824-9FBFB0117CF8Q36311571-9002E3F0-6E33-4D78-AD3E-A715148A8C17Q36417824-8D271D6A-8311-4651-9A38-4A6137145FD9Q36521161-C786DC6C-DF4E-48AD-A532-86065C03FD76Q37715584-F6F3BC00-22E0-403C-96EB-342BFE538829Q37822185-29B6879C-EE9A-4A07-B2E7-D649BE448EA1Q38014516-20235128-87D5-4B03-9C83-298C96CA16F8Q38038658-84DC8AC4-D7B7-4C97-A081-26795737253DQ38190489-720866D6-D71C-46B3-B7E7-2E3AF02B46ECQ38900824-B68B7FE3-C978-402A-9383-B08035CC9A71Q39035715-46F9D5E9-25D1-42B7-B2DF-B8C3348128E4Q40215964-5E56A070-2E94-41BD-9539-A1E1E27DBC5DQ41054906-7C47F8A6-47D5-4843-A175-653BF19618DEQ41978504-A5008A47-2329-47E8-8C21-2373F9E2981CQ42460944-F59CE56E-7527-44CA-8800-E6C4831A7D03Q43028047-D51B1E34-1CF8-414A-AEFF-68F8583247CEQ47096488-7AC5C50F-637F-4A66-B163-3BF74CEA8FE0Q50088043-CCC4C8B6-FB69-4953-BC52-55B5D1533EC7Q52780711-C0C16189-4486-4C89-B967-6FD3785E18E2Q53445736-007F72DA-861E-4EA7-827E-7175568ED173
P2860
Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@ast
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@en
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@nl
type
label
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@ast
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@en
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@nl
prefLabel
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@ast
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@en
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@nl
P2860
P3181
P1433
P1476
Chronic antidiabetic sulfonylu ...... on mouse pancreatic beta-cells
@en
P2093
Colin G Nichols
Maria Sara Remedi
P2860
P3181
P356
10.1371/JOURNAL.PMED.0050206
P407
P577
2008-10-28T00:00:00Z